ArticleJournal of nanobiotechnology2006
Canine parvovirus-like particles, a novel nanomaterial for tumor targeting.
Article in Journal of nanobiotechnology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 119 citations in OpenAlex.
- Article
- Modification of a Tumor-Targeting Bacteriophage for Potential Diagnostic Applications.Molecules (Basel, Switzerland) · 2021Article
- A smart viral vector for targeted delivery of hydrophobic drugs.Scientific reports · 2021Article
- Nano drug delivery systems in upper gastrointestinal cancer therapy.Nano convergence · 2020Review
- Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation.Virulence · 2020Article
- Study of the immunogenicity of the VP2 protein of canine parvovirus produced using an improved Baculovirus expression system.BMC veterinary research · 2020Article
- Oncolytic Viruses for Canine Cancer Treatment.Cancers · 2018Review
- Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.International journal of nanomedicine · 2017Review
- Transcriptome profiling indicating canine parvovirus type 2a as a potential immune activator.Virus genes · 2016Article
- Design of virus-based nanomaterials for medicine, biotechnology, and energy.Chemical Society reviews · 2016Review
- Magnetic Resonance Imaging Revealed Splenic Targeting of Canine Parvovirus Capsid Protein VP2.Scientific reports · 2016Article
- Biomimetic strategies for targeted nanoparticle delivery.Bioengineering & translational medicine · 2016Review
- Trial Watch-Oncolytic viruses and cancer therapy.Oncoimmunology · 2016Review
- The application of virus-like particles as vaccines and biological vehicles.Applied microbiology and biotechnology · 2015Review
- Role of capsid proteins in parvoviruses infection.Virology journal · 2015Review
- A review on emerging diagnostic assay for viral detection: the case of avian influenza virus.Molecular biology reports · 2015Review
- Quantum Dots Encapsulated with Canine Parvovirus-Like Particles Improving the Cellular Targeted Labeling.PloS one · 2015Article
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Review
- Using viruses as nanomedicines.British journal of pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Specific targeting of tumor cells is an important goal for the design of nanotherapeutics for the treatment of cancer. Recently, viruses have been explored as nano-containers for specific targeting applications, however these systems typically require modification of the virus surface using chemical or genetic means to achieve tumor-specific delivery. Interestingly, there exists a subset of viruses with natural affinity for receptors on tumor cells that could be exploited for nanotechnology applications. For example, the canine parvovirus (CPV) utilizes transferrin receptors (TfRs) for binding and cell entry into canine as well as human cells. TfRs are over-expressed by a variety of tumor cells and are widely being investigated for tumor-targeted drug delivery. We explored whether the natural tropism of CPV to TfRs could be harnessed for targeting tumor cells. Towards this goal, CPV virus-like particles (VLPs) produced by expression of the CPV-VP2 capsid protein in a baculovirus expression system were examined for attachment of small molecules and delivery to tumor cells. Structural modeling suggested that six lysines per VP2 subunit are presumably addressable for bioconjugation on the CPV capsid exterior. Between 45 and 100 of the possible 360 lysines/particle could be routinely derivatized with dye molecules depending on the conjugation conditions. Dye conjugation also demonstrated that the CPV-VLPs could withstand conditions for chemical modification on lysines. Attachment of fluorescent dyes neither impaired binding to the TfRs nor affected internalization of the 26 nm-sized VLPs into several human tumor cell lines. CPV-VLPs therefore exhibit highly favorable characteristics for development as a novel nanomaterial for tumor targeting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.